Menu Search
Equities

AC Immune SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IMR:FRA

AC Immune SA

Actions
  • Price (EUR)2.53
  • Today's Change-0.075 / -2.88%
  • Shares traded4.00
  • 1 Year change+0.80%
  • Beta1.6268
Data delayed at least 15 minutes, as of Feb 10 2026 07:04 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

  • Revenue in USD (TTM)5.71m
  • Net income in USD-93.84m
  • Incorporated2003
  • Employees133.00
  • Location
    AC Immune SAEPFL Innovation Park, Building BLAUSANNE 1015SwitzerlandCHE
  • Phone+41 213459121
  • Fax+41 213459120
  • Websitehttps://www.acimmune.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.